Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verastem, Inc. - Common Stock (NQ:VSTM)

6.170 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 502
Open 6.170
Bid (Size) 6.170 (2)
Ask (Size) 6.360 (8)
Prev. Close 6.170
Today's Range 6.170 - 6.170
52wk Range 2.100 - 8.450
Shares Outstanding 44,784,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Verastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns Bullish
In a study conducted in China, GFH375, also known as VS-7375 in the U.S., showed an overall response rate of 52% in patients with pancreatic ductal adenocarcinoma and 42% in those with non-small cell... 
Via Stocktwits
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga

Performance

YTD
-4.9%
-4.9%
1 Month
-11.7%
-11.7%
3 Month
+11.0%
+11.0%
6 Month
+57.8%
+57.8%
1 Year
+53.5%
+53.5%

More News

Read More
Nasdaq Edges Higher; ISM Manufacturing PMI Falls In May
Via Benzinga
What's Going On With Verastem Oncology Stock On Monday?
Via Benzinga
Which stocks are experiencing notable movement on Monday?
Via Chartmill
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor
From Verastem Oncology
Via Business Wire
Verastem Oncology to Present at the Jefferies Global Healthcare Conference
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma
From Verastem Oncology
Via Business Wire
Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire
FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer
Via Benzinga
Exposures Product Safety
Verastem’s Combination Therapy For Ovarian Cancer Gets FDA Approval: Retail’s Pleased
Via Stocktwits
Exposures Product Safety
FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
Verastem Oncology to Present at Upcoming Investor Conferences
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces $75 million Private Placement
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors
From Verastem Oncology
Via Business Wire
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025
From Verastem Oncology
Via Business Wire
Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire
Hallador Energy, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
From Verastem Oncology
Via Business Wire
Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference
From Verastem Oncology
Via Business Wire
Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers
From Verastem Oncology
Via Business Wire

Frequently Asked Questions

Is Verastem, Inc. - Common Stock publicly traded?
Yes, Verastem, Inc. - Common Stock is publicly traded.
What exchange does Verastem, Inc. - Common Stock trade on?
Verastem, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Verastem, Inc. - Common Stock?
The ticker symbol for Verastem, Inc. - Common Stock is VSTM on the Nasdaq Stock Market
What is the current price of Verastem, Inc. - Common Stock?
The current price of Verastem, Inc. - Common Stock is 6.170
When was Verastem, Inc. - Common Stock last traded?
The last trade of Verastem, Inc. - Common Stock was at 06/04/25 04:00 PM ET
What is the market capitalization of Verastem, Inc. - Common Stock?
The market capitalization of Verastem, Inc. - Common Stock is 276.32M
How many shares of Verastem, Inc. - Common Stock are outstanding?
Verastem, Inc. - Common Stock has 276M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.